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Abstract
Somatic activating mutations in the Notch1 receptor result in the overexpression of activated Notch1, which can be
tumorigenic. The goal of this study is to understand the molecular mechanisms underlying the phenotypic changes caused
by the overexpression of ligand independent Notch 1 by using a tetracycline inducible promoter in an in vitro embryonic
stem (ES) cells/OP9 stromal cells coculture system, recapitulating normal hematopoiesis. First, an in silico analysis of the
promoters of Notch regulated genes (previously determined by microarray analysis) revealed that the motifs recognized by
regulatory proteins known to mediate hematopoiesis were overrepresented. Notch 1 does not bind DNA but instead binds
the CSL transcription factor to regulate gene expression. The in silico analysis also showed that there were putative CSL
binding sites observed in the promoters of 28 out of 148 genes. A custom ChIP-chip array was used to assess the occupancy
of CSL in the promoter regions of the Notch1 regulated genes in vivo and showed that 61 genes were bound by activated
Notch responsive CSL. Then, comprehensive mapping of the CSL binding sites genome-wide using ChIP-seq analysis
revealed that over 10,000 genes were bound within 10 kb of the TSS (transcription start site). The majority of the targets
discovered by ChIP-seq belong to pathways that have been shown by others to crosstalk with Notch signaling. Finally, 83
miRNAs were significantly differentially expressed by greater than 1.5-fold during the course of in vitro hematopoiesis. Thirty
one miRNA were up-regulated and fifty two were down-regulated. Overexpression of Notch1 altered this pattern of
expression of microRNA: six miRNAs were up-regulated and four were down regulated as a result of activated Notch1
overexpression during the course of hematopoiesis. Time course analysis of hematopoietic development revealed that cells
with Notch 1 overexpression mimic miRNA expression of cells in a less mature stage, which is consistent with our previous
biological characterization.
Citation: Hamidi H, Gustafason D, Pellegrini M, Gasson J (2011) Identification of Novel Targets of CSL-Dependent Notch Signaling in Hematopoiesis. PLoS
ONE 6(5): e20022. doi:10.1371/journal.pone.0020022
Editor: Eliana Saul Furquim Werneck Abdelhay, Instituto Nacional de Ca ˆncer, Brazil
Received March 23, 2011; Accepted April 8, 2011; Published May 26, 2011
Copyright:  2011 Hamidi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors have no support or funding to report.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: jgasson@mednet.ucla.edu
Introduction
Notch proteins are single-pass, heterodimeric, transmembrane
proteins encoded by genes which are conserved from flies to
humans. Notch plays a critical role in development mediated by
cell-cell interaction. Upon binding of a ligand (a single pass
transmembrane protein on a neighboring cell) the Notch receptor
undergoes a series of proteolytic cleavages resulting in the release
of the Notch intracellular domain (NICD). The NICD translocates
to the nucleus and activates the transcription of target genes by
turning the CSL transcription factor from a repressor to an
activator [1] (reviewed in Kopan et al.).
Aberrant Notch signaling has been associated with many
cancers including leukemia [2], breast cancer [3], medulloblasto-
ma [4], melanoma [5] and pancreatic cancer [6] . In some reports
it has been described as tumorigenic while in other reports it’s
been described as having tumor suppressor function. In leukemia
the discovery of the (7;9) chromosomal translocation [7] showed
that constitutively active Notch signaling can be tumorigenic.
Although the translocation was later found in less than 1% of
T-ALL, somatic activating mutations in Notch1 receptor were
detected in over 50% of human T-ALL cases [2] and 74% of
tumors in a mouse leukemia model [8], showing that overexpres-
sion of activated Notch1 is indeed tumorigenic [9].
One possible mechanism of oncogenesis is the disruption of
CSL binding homeostasis. An abundance of NICD has been
shown to stoichiometrically deplete CSL from other binding
partners and their associated genomic loci leading to aberrant
gene regulation at those sites (10). CSL can associate with at least
one partner other than Notch, p48/PTF1a [10,11,12]. This
disruption may lead to altered gene regulation of target genes that
are important in regulating growth. A genome wide assessment of
CSL in the mammalian genome has not yet been performed to
assess which genes are regulated by CSL.
Furthermore, it has been demonstrated that Notch signaling is
context dependent in cancer, based on its integration with other
signaling pathways. The Notch pathway has been shown to
crosstalk with Wnt, Cadherin and the Sonic Hedgehog pathways
which have been associated with tumor formation in a variety of
cancers. When Notch was activated at different stages of
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Notch1 were cell type specific and dependent on the other signals
[13]. We wanted to assess CSL binding sites globally to examine if
they are found in the regulatory region of genes mediating
important signaling pathways and if CSL binding sites are
distributed throughout the genome indicating that Notch signaling
is integrating with signaling pathways at the level of transcription.
The molecular mechanism underlying the function of Notch1 in
disease and developmental states has been investigated by
identification of either the direct targets of Notch1 or the direct
targets of the effector protein of Notch1 signaling CSL. An
integrated systems biology approach was used to assess the direct
targets of Notch1 during leukemic cell growth [14]. First,
differentially regulated genes were determined using microarray
analysis comparing gene expression profiles of seven T-ALL cell
lines treated with either DMSO or a highly active gamma
secretase inhibitor. This was followed by identifying the direct
targets of Notch1 in the HPB-ALL T-ALL cell line using a ChIP
on chip (ChIP-chip) analysis using a spotted promoter array
platform. Although the microarray analysis identified differential
expression of several known direct targets of Notch signaling their
ChIP-Chip analysis could not confirm promoter occupancy of
Deltex1, Hes1 nor Notch3 by NICD. This may be a reflection of
the array platform which only included the proximal promoter
regions (2700 to +200 bp). For example, only 18% of MYC-
binding sites were found to be within 1 kb of a 59-exon using an
oligonucleotide tiling array that encompasses chromosomes 21 and
22 [15]. Any binding site outside of the core promoter regions
would be missed by this analysis which may include many well
defined targets of Notch signaling.
Notch 1 does not bind DNA and therefore assessing the
occupancy of Notch1 at the promoters of target genes may be
limited by the technical difficulty of the Notch 1 antibody IP. The
Bray group sought to assess the direct targets of Notch signaling by
assessing the promoter occupancy of the Notch 1 effector protein
CSL in Drosophilia DMD8 cells [16] . The DMD8 cell model was
used to assess global changes in mRNA expression (microarray
analysis) and genome wide occupancy of CSL (Su(H) in Drosophila)
within 30 min of activating Notch using ChIP-chip analysis in
hopes of identifying direct target of CSL dependent Notch
signaling. Although, their genome wide promoter occupancy
analysis benefited from the use of an array that tiled the Drosophila
genome to give a more complete assessment of Notch target genes,
it still suffers from the general limitation of ChIP-chip technology
including probe selection bias and hybridization bias. Only 262
significant Su(H) binding peaks were identified genome wide.
Computational analysis of the tiling array was based on a method
to detect peaks in a dense tiling array which included tiling one 50-
mer every 38 bp [17] . However, the array used by the Bray group
included 60 base oligonucleotide probes printed for approximately
every 300 bp of the genomic DNA and thus it would likely miss
true positive because of the limitation of the array. A significant
peak was defined as a region that was detected in five adjacent
probes which corresponds to 1.5 kb region. Even though, there
was a statistical enrichment of Su(H) sites in the peaks they
identified, only 27% of the binding-site clusters identified
computationally and 1.08% of high scoring Su(H) binding sites
in noncoding regions were identified as occupied.
Assessing transcription factor binding sites genome-wide has
only become possible the last few years. High-throughput
sequencing combined with Chromatin Immunoprecipitation has
become the gold standard for assessing transcription factor binding
sights globally in vivo. It is preferred over ChIP-chip because it is an
absolute rather than a relative assessment of the genomic loci
bound by the protein of interest. With ChIP-seq you actually
sequence the ChIP purified DNA instead of hybridizing it to set of
preselected probes.
Genome wide occupancy of CSL will also be important in
assessing if Notch is regulating microRNAs which are important
regulators of development. MicroRNAs (miRNA are short (19–25
nucleotides in lenght) noncoding RNAs, that regulate gene
expression by either inhibiting translation or marking specific
mRNA for degradation [18,19]. MiRNAs influence gene expres-
sion as broadly as transcription factors and have been shown to
play a role in regulating development [19]. MiRNA target
predictions have indicated that miRNA may target nearly 30%
of animal genes [20,21,22]. Thus, its not surprising that
perturbation in their homeostatic function has been associated
with many diseases including cancer [23,24,25]. The miR-15a and
miR-16-1 genes target B cell lymphoma 2 (Bcl2), an antiapoptotic
gene and thus loss of their expression has been associated with
cancer [26,27]. Some miRNAs such at the miR17–92 locus 13q31
were shown to have oncogenic potential because they are
amplified in some tumor [28] and their overexpression in a
mouse model actually accelerated tumorigenesis [28,29].
MiRNAs play an important role in regulating hematopoiesis
[30]. MiR-142 was highly expressed in all hematopoietic tissues
whereas miR-223 was expressed exclusively in the bone marrow
which consists of hematopoietic stem cells and myeloid, erythroid
and lymphoid cells at different stages [30]. MiR-223 is also
associated with myeloid differentiation [31]. Other groups have
also implicated miR-144, miR-150, and miR-155 in hematopoiesis
[32]. MiR-126 has been associated with megakaryocyte differen-
tiation [33]. The miR-144/451 cluster is upregulated during
erythropoiesis and is under the control of the master erythrocyte
regulator GATA-1 [34,35].
The crosstalk between microRNA expression and Notch
signaling hasbeen reported in terms of which microRNAs target
the Notch pathway or its target genes. Mir-34a has been
reported to downregulate Notch-1 Notch-2, and CDK6 protein
expression [36]. MiR-1 negatively regulates Delta-1 protein
levels in mouse embryonic stem cells [37]. MiR-1995b down
regulates the down stream Notch target gene Hes-1 [38]. These
miRNA have been studied as potential therapeutic targets for
cancer. However, in leukemia, its not abberrent gene regulation
that leads to constititutively active Notch-1 expression, its
somatic activating mutations in the receptor which allows the
receptor to have increase stability. Therefore, finding miRNAs
that are regulated by Notch signaling may be another potential
therapeutic target.
CSL is a unique transcription factor because it is bound
regardless of the presence of activated Notch. A conventional
ChIP with antibodies to CSL alone would be limiting because the
effect of Notch signaling would not be gauged. Furthermore, it
would be difficult to discern real CSL binding sites from artifacts.
A sequential ChIP is a new method that allows one to assess
transcription factor binding occupancy using two IgGs. A hallmark
of Notch activation is the acetylation of H4. Thus, a sequential
ChIP with antibody to acetylated H4 followed by antibody against
CSL will identify activated Notch responsive CSL binding sites.
Furthermore, CSL is a small protein 60 kDa and bound to DNA
in the presence of either repressor complexes or activation
complexes which are enormous in size. A sequential ChIP,
especially since the first IP is against the readily accessible
acetylated H4 would help reduce the complexity of the nuclear
lysate to allow for optimal IP with CSL antibody in the second IP.
This will possibly overcome the technical difficult associated with
performing a ChIP against CSL.
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the biology of tissue development and may serve as potential
therapy for diseases such as cancer. The study of the murine
hematopoietic system has resulted in the major technological
advances in deriving mature tissues from embryonic stem (ES) cells
[39] and its further characterization will have implications beyond
the study of the blood system. The induction of hematopoietic
differentiation on stromal cells [40] and formation of embryoid
bodies (EB) [41,42] are the two experimental systems used to
generate hematopoietic precursors from embryonic stem cells in
most experiments [43]. We have previously modeled murine
hematopoiesis using an embryonic stem cells (ES)/OP9 coculture
which was shown to be a highly reproducible way to model
hematopoiesis in vitro [40,44,45,46]. The OP9 stroma cell line
provides the necessary extrinsic signals for the differentiation of
pluripotent ES cells first into primitive flk1+ hemangioblasts (day
4–5) and then immature hematopoietic stem and progenitor cells
(day 8). We have shown that the overexpression of ligand
independent Notch1 in flk1+ hemangioblasts results in an
alteration of the phenotype of the day 8 hematopoietic progenitor
cells characterized by cell morphology, flow cytometry and gene
expression profiling.
The goal of this study is to understand the molecular
mechanism underlying the phenotypic changes caused by the
expression of ligand independent Notch 1. First, we performed an
in silico analysis of the promoters of 148 previously identified Notch
regulated genes to determine the presence of putative regulatory
regions. Then, a custom ChIP-chip array was used to assess the
occupancy of CSL in the promoter regions of these 148
differentially expressed genes. Finally, a comprehensive mapping
of the CSL binding sites genome-wide was determined using
ChIP-seq analysis. Given that miRNA have documented roles in
hematopoietic development, we wanted to assess which miRNAs
are regulated during normal hematopoiesis and which miRNA are
differentially regulated by overexpression of Notch. Thus, we
performed expression profile analysis of microRNAs, using
microRNA microarray during normal hematopoiesis and in
response to overexpression of ligand independent Notch1.
Results
Identification of putative regulatory motifs in the
upstream regions of differentially expressed genes
Our lab previously utilized an in vitro murine embryonic stem
cell co-culture system to study the effects of activated Notch 1 on
normal hematopoietic differentiation. A tetracycline-inducible
system regulating expression of a ligand independent, constitu-
tively active form of Notch1 was introduced into murine E14Tg2a
ES cells. The ES cells were co-cultured with OP9 stromal cells to
induce the ES cells to differentiate first to hemangioblasts and
subsequently to hematopoietic progenitors. During days 5 to 8 of
the co-culture flk1+ hemangioblasts develop into hematopoietic
progenitors, which then go on to form mature myeloid and
erythroid cells. Previously we showed that overexpression of ligand
independent Notch1(Notch On), a phenotype mimicking the
abnormal expression of Notch1 in leukemia [9] , leads to a distinct
phenotype that can be characterized by flow cytometry analysis
(over-expression of Notch 1 preserves cells in a less mature state)
and gene expression profiling [45].
Global gene expression profiling of day 8 hematopoietic
progenitors in the absence and presence of activated Notch
yielded 158 differentially-regulated candidate genes [45] as both
direct and indirect putative downstream targets of oncogenic
forms of Notch. The Panther Database system [47] was used to
identify Gene Ontology (GO) Biological Process categories for the
158 differentially regulated genes to identify the pathways
regulated by Notch. Not surprisingly eight of the genes mapped
to the Notch pathway (Table 1). Although only the Notch,
Angiogenesis and Alzheimers disease-presenilin pathways were
significantly over-represented (P-value,0.01), the Panther analysis
showed that the 68 classified genes represented multiple important
signaling pathways such as the Wnt, Cadherin, TGFbeta and
Integrin pathways, all known to be important signaling pathways
in development. Of the 158 genes, 90 were categorized as
unclassified.
To further assess which factors may be involved in or impacted
by the differential regulation of the 158 genes we performed an in
silico analysis of their promoter regions. CLOVER is an algorithm
developed by Frith et al. to identify transcription factor binding
sites that are statistically over- or under-represented in a group of
sequences. We used CLOVER to assess whether the binding sites
of known regulatory proteins compiled in the JASPAR library
were over or under-represented in the set of sequences
representing 1.5 kb upstream of the promoters of 148 of the 158
regulated genes. The results showed that there were 13 motifs,
including the CSL motif, that were over-represented and 2 motifs
that were under-represented in the 158 differentially expressed
genes (Table 2).
Twelve out of thirteen regulatory proteins recognizing the over-
represented motifs have previously been shown to have a role in
stem cell differentiation while 8/13 (KLF4, Nkx2.5, Zfp98, Fox2a,
CSL, Hhex, Nfya, Cebpg) have been shown to have a role in
hematopoiesis specifically. Furthermore, the two underrepresented
motifs (Gata2 and Yy1) also play critical roles in hematopoietic
development. It seems likely that they are under-represented in
this experiment because they play a role in the later steps of
hematopoiesis whereas activated Notch 1 signaling preserves the
cells in a less differentiated state.
The microarray data were searched to determine if the genes
encoding the transcription factors associated with the 13 over-
represented and 2 under-represented motifs were transcribed in
the cells and if they were differentially regulated by activated
Notch. 9/13 transcription factors whose TFBS were over-
represented had mRNA levels higher than the arbitrary cutoff of
500 (Table 3). Both of the transcription factors that were under-
represented also had mRNA levels higher than 500. However,
only KLF4 was differentially regulated by Notch showing an
increase in expression of almost 3 fold.
Occupancy of CSL binding sites in the upstream regions
of differentially expressed genes
Twenty eight of the 148 Notch regulated genes had a putative
CSL Binding Site within their promoter (defined as the sequence
1.5 kb upstream of their transcriptional start site) (TSS) (Table 4).
The list includes known targets of Notch signaling such as Hey1,
Hes1 and Notch 1 (shown in the bold type) along with a cohort of
novel targets including wnt4. Gene ontology analysis (data not
shown) indicates that known targets of Notch signaling are
enriched along with the presenilin processing pathway. Members
of the Wnt, Integrin and Cadherin pathways are present among
the list.
A modified ChIP procedure was used to assess CSL occupancy
in the upstream region of of Notch regulated genes in vivo. Two
major modifications were made to the ChIP procedure in these
experiments. Notch is thought to modify the function of CSL and
not it’s binding to the DNA; association of the Notch ICD with
bound CSL protein changes its function from a repressor to an
activator. Therefore, we added an extra IP step to the standard
Novel Targets of Notch Signaling in Hematopoiesis
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NCBI:Mm Microarray
Pathways ##Expected P value
Unclassified 26616 90 116.55 5.84E-08
Notch signaling pathway 52 8 0.23 1.98E-08
Angiogenesis 258 7 1.13 0.0259
Alzheimer disease-presenilin pathway 143 6 0.63 0.00743
Integrin signaling pathway 263 6 1.15 0.188
Wnt signaling pathway 408 5 1.79 1
TGF-beta signaling pathway 154 4 0.67 0.813
Cadherin signaling pathway 204 3 0.89 1
Apoptosis signaling pathway 187 3 0.82 1
Insulin/IGF pathway-protein kinase B signaling cascade 89 2 0.39 1
Insulin/IGF pathway-MAP kinase cascade 77 2 0.34 1
Blood Coagulation 69 2 0.3 1
p38 MAPK pathway 61 1 0.27 1
p53 pathway 135 1 0.59 1
T cell activation 168 1 0.74 1
Nicotine acetylcholine receptor signaling pathway 104 1 0.46 1
Muscarinic acetylcholine receptor 2 and 4 signaling pathway 63 1 0.28 1
Arginine biosynthesis 6 1 0.03 1
Interleukin signaling pathway 169 1 0.74 1
Inflammation by chemokine and cytokine signaling pathway 337 1 1.48 1
FAS signaling pathway 45 1 0.2 1
Endothelin signaling pathway 97 1 0.42 1
EGF receptor signaling pathway 153 1 0.67 1
Cytoskeletal regulation by Rho GTPase 135 1 0.59 1
Axon guidance mediated by netrin 42 1 0.18 1
doi:10.1371/journal.pone.0020022.t001
Table 2. Significant JASPAR motifs over and under represented within 1.5 kb upstream of TSS of Notch regulated genes.
ChipSeq Peaks DNA Binding Site (TFBS) TF Gene ID Function
Over-Represented (p-value ,0.01)
1 CSL Binding Motif CSL NM_009035 Mediator of Notch Signaling
1 Gklf ZN-FINGER, C2H2 Klf4 U20344 Hematopoiesis (Earyl Erythropoiesis) [48]
1 Pax-4 PAIRED-HOMEO Pax4 AF031150 Different. of pancreatic islet beta [49]
1 BC 1-4 ZN-FINGER, C2H2 Kbtbd4 NM_025991 N/A
1 HNF-3beta FORKHEAD Foxa2 NM_010446 Early Embryogensis [50]
1 MZF_1-4 ZN-FINGER, C2H2 Zfp98 NM_016793 Hematopoiesis (Myelopoiesis) [51]
1 MEF2 MADS Mef2a AV255689 Myogenesis [52]
0 Athb-1 HOMEO-ZIP Hhex AK014111 Hematopoiesis [53]
1 Nkx HOMEO Nkx2-5 NM_008700 Cardiac development [54], leukemogenesis [55]
0 NF-Y CAAT-BOX Nfya NM_010913 Promotes HSC self-renewal [56]
0 SRY HMG Sox3 NM_009237 Neuronal Development [57]
1 HNF-1 HOMEO Tcf1/HNF1 NM_009327 Pancreatic Development [58]
1 cEBP bZIP Cebpg BC011319 Hematopoiesis (Myelopoiesis) [59]
Under-Represented (p-value ,0.01)
1 Yin-Yang ZN-FINGER, C2H2 Yy1 NM_009537 myeloid transforming gene [60]
1 GATA-2 ZN-FINGER, GATA Gata2 NM_008090 hematopoietic differentiation[61]
doi:10.1371/journal.pone.0020022.t002
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promoters using an antibody that recognizes acetylated Histone
H4. Acetylation of both Histone H3 and H4 is a hallmark of
transcriptional activation [62,63], mediated in part by p300, a co-
activator that is a component of the NICD:CSL transcriptional
activation complex [64]. Using this 2 step IP ChIP procedure (Re-
ChIP) activated Notch responsive CSL occupancy was identified.
For the second modification to the standard ChIP protocol,
ChIP purified DNA fragments were hybridized to a custom high
density oligonucleotide array which consisted of tiled, 50 bp
probes constituting 1.5 kb of DNA sequence upstream of the
transcriptional transcription start site (TSS) of 148 of the 158
genes identified by microarray analysis (sequences were not
available for the remaining 10 genes). DNA isolated from the
two-step ChIP procedure (Re-ChIP)using cells exposed to
activated Notch (Notch On) and control cells (Notch Off) were
hybridized to this custom array. Experimental conditions were
the same as those used to isolate the RNA and generate the list of
158 Notch regulated genes (original microarray analysis). Since
each probe was present at least twice, a quality assessment of the
in-array variability was controlled by only including probes with a
CV of less than 30%.
Activated Notch responsive CSL binding was determined using
the ChIPOTLE algorithm to identify peaks using the Notch On/
Notch Off signal from the ChIP-chip. The ChIPOTLe algorithm
has been used to analyze yeast ChIP-chip data generated on
whole-genome tiling arrays
33 The Gaussian distribution was used
to model the background and P value of 0.01(corrected for
multiple testing). The results show that of the 148 tested genes, 61
genes were bound by activated Notch responsive CSL (Table 5).
As a control a single IP ChIP with only CSL was analyzed
under the same parameters and as expected there were no peaks
detected when comparing experimental to control conditions. This
result is expected as CSL is thought to be bound to its TFBS in
both the presence and absence of Notch. In the presence of Notch
the complex is converted from a repressor to an activator
recognized by the acetylated H4 antibody.
Genome wide mapping of CSL binding sites during
hematopoiesis
To generate genome wide maps of CSL binding in vivo, Re-
ChIP purified DNA fragments were isolated from control cells and
cells with activated Notch1 overexpressed from Day 5 to Day 8 as
previously reported. The experimental condition were the same as
as those used to generate Re-ChIP fragments for the ChIP-chip
analysis and to isolate the RNA for the original microarray
analysis.
These ChIP purified DNA fragments were then sequenced
using massive parallel sequencing instead of hydbridizing them to
an array. An experiment sequenced in technical triplicates resulted
in 36 base pair (bp) sequence reads which were aligned to the
reference mouse genome. 72.9% of the Notch On and 83.9% of
the Notch Off uniquely mapped reads aligned to the genome with
zero-mismatches. Figure 1 shows that the unique reads mapped
preferentially to regions within 1.5 kb from the transcriptional
start sites indicating that the Re-ChIP DNA fragments are
enriched in the proximal promoter of genes instead of randomly
distributed.
The unique reads were used to identify regions of the genome
with significant enrichment in CSL associated DNA sequenced
using a peak finding algorithm. A peak was defined as a 1000 bp
region with a P-value less than 10
212 along with a window
mapability of greater than 25% and sense/antisense strand count
within 30%. Screenshots of ChIP-seq reads using the genome
browser show that ChIP-seq reads map upstream of known targets
of Notch such as the Myc [65]oncogene (Figure 2a), Hey1 [66]
(Figure 2b) and Hes1 [66](Figure 2c) as well as novel targets such
as Mns1(Figure 2d).
To associate peaks with genes, a distance criteria from the
transcriptional start site (TSS) was used ranging from +/2 20 Kb
Table 3. Regulatory proteins are not transcriptionally regulated by Notch.
Microarray Fold Change mRNA Levels
DNA Binding Site Associated Protein Gene ID ON/OFF SD OFF ON
Over-Represented (p-value,0.01)
CSL Binding motif CSL NM_009035 0.8 0.2 2803.4 2179.6
Gkfl ZN-FINGER, C2H2 Klf4 U20344 2.8 1.4 1582.2 4932
Pax-4 PAIRED-HOMEO Pax4 AF031150 2 1.1 17.6 35.1
Broad-complex1-4 ZN-FINGER Kbtbd4 NM_025991 1 0 2188.4 2405.5
HNF-3beta FORKHEAD Foxa2 NM_010446 1.5 1.1 382.3 458.3
MZF_1-4ZN-FINGER, C2H2 Zfp98 NM_016793 1.8 1 41.2 63.3
MEF2 MADS Mef2a AV255689 1 0.1 4377.5 4940
Athb- 1 HOMEO-ZIP Hhex AK014111 0.7 0.1 8542.9 6399.7
Nkx HOMEO Nkx2.5 NM_008700 1.2 0.4 528.6 648
NF-Y CAAT-BOX Nfya NM_010913 0.7 0 1351.6 1077
SRY HMG Sox3 AF434675 0.6 0.4 148.5 52
HNF-1 HOMEO Tcf1/HNF1 NM_009237 4.2 4.1 111.2 277
cEBP bZIP Cebpg BC011319 1.2 0.4 494 596.5
Under-represented (p-value.0.99)
Yin Yang ZN-FINGER, C2H2 Yy1 0.9 0.1 11616 11426.3
GATA-2 ZN-FINGER, GATA Gata2 1 0.1 2651.4 2815.4
doi:10.1371/journal.pone.0020022.t003
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number of genes with at least one peak within 10 kb. The ‘‘ON’’
only circle contains those genes that had a peak in cells expressing
activated Notch and lacked a peak in the control cells. The ‘‘OFF’’
only circle are those genes that had a peak in the control cells and
but not one in the cells expressing activated Notch. The ‘‘Both’’
circle indicates those genes that had a peak that was present in the
activated Notch cells as well as the control cells. The cross-section
indicates genes with multiple types of peaks. For example genes in
the cross section of the ‘‘On’’ only circle and the ‘‘Off’’ only circle
have at least one On only binding site and at least one Off only
binding site. A total of 3077 genes had all three different types of
peaks within 10 kb of their transcriptional start site. There were 540
genes that had CSL bound in normal cells but not in cells with
constitutively active Notch.
Gene ontology analysis was performed to categorize the
putative functions of genes contained in the ‘‘On’’ only category
using Panther [47] to focus in on targets of overexpression of
activated Notch1. Table 6 suggests crosstalk between Notch and
several highly conserved pathways important in development at
the level of transcription. Notch has been shown previously to
integrate with these pathways including the PDGF signaling
pathway (P-value=4.44610
26), ubiquitin proteasome pathway
(P-value=9.5610
26), p53 pathway (P-value=1.79610
25), Ras
pathway (P-value=3.06610
24), and cell cycle pathways (P-
value=1.32610
23) in controlling development [47]. 18 out of 19
pathways were shown to crosstalk with Notch in previous studies
(Table 6). A substantial number of genes do not have gene
ontology annotations and are listed as unclassified. Finally,
Table 7 shows the pathways sorted by number of genes in the
pathway that are regulated by Notch and is used mainly as a
classification tool. This table is to simply list the pathways
represented by the genes with at least one On only peak. A
substantial number of genes do not have gene ontology
annotations and are listed as unclassified.
Of the 148 Notch regulated genes identified by microarray and
assessed by ChIP-chip, 59 were shown by ChIP-seq to be bound
by activated Notch responsive CSL and 28 out of 54 (52%) were
common to ChIP-chip and ChIP-seq (Table 8). Although 52%
overlap was significant (P-value less than 0.02), ChIP-seq may be
missing peaks because 1) the ChIP-chip approach would be more
likely to identify weaker sites because of the custom array tiled
each 1.5 kb region with a higher resolution (at least 30 probe
duplicate probes per 1.5 kb region whereas ChIPseq unique reads
mapped about 1 read per 1 kb), 2) peaks near repetitive regions
would not be identified by ChIP-seq.
miRNA are differentially regulated during normal
hematopoiesis
MicroRNA are important regulator of hematopoiesis and we
wanted to assess which microRNA are differentially expressed
during hematopoiesis in our in vitro murine embryonic stem cell
co-culture system. Expression profiles of miRNA during normal
hematopoietic differention were examined using a commercial
miRNA microarray that contained all miRNA present in the
miRBase miRNA registry release 8.1 [98,99]. To assess if miRNA
are differentially regulated during normal hematopoiesis, the
expression profile of miRNA from hematopoietic progenitors (day
8) were compared to flk1+ hemangioblasts (day 5). Each time point
was represented by two independent biological samples and two
technical replicates. Microarray analysis revealed that 83 miRNAs
were significantly differentially expressed by greater than 1.5-fold
during the course of hematopoiesis in vitro from day 5 to day 8
(table S1). Thirty one miRNA were up-regulated and fifty two
were down-regulated. The differentially regulated miRNA cluster
into groups (see figure 4a).
Analysis of activated Notch 1 responsive CSL binding to
miRNA loci
To assess if miRNA expression was influence by the Notch
pathway, CSL binding sites were mapping to within 2 kb of
either the genomic loci or the promoter region of all known
miRNA. We assessed if the ChIPseq derived CSL binding site
were mapping in the high-confidence microRNA promoters
described by the Young lab which represented over 80% of
miRNA [100]. There were 37 miRNA with at least one binding
site within 2 kb of their transcription start site (Table S2). There
were several binding sites that were mapped onto the start of
miRNAs (data not shown).
Table 4. Notch regulated genes with a putative CSL Binding
Site within 1.5 kb upstream of TSS.
Microarray Fold
Change Genbank GENE_SYMBOL
56.27 NM_008570 MCPT1
47.23 NM_008182 GSTA2
22.97 NM_010423 HEY1
12.27 NM_008182 MCPT1
6.11 NM_013749 TNFRSF12A
5.04 NM_009523 WNT4
4.66 NM_010664 KRT18
4.52 NM_013464 AHR
4.02 NM_013749 TNFRSF12A
3.88 BC004651 GM2A
3.84 NM_008714 NOTCH1
3.69 NM_021334 ITGAX
3.34 NM_010299 GM2A
3.34 U03561 HSPB1
3.33 BC013560 COL4A2
3.11 NM_080858 ASB12
3.08 NM_008086 GAS1
3.08 AK019971 PRRX2
2.98 NM_134163 MBNL3
2.80 NM_013905 HEYL
2.40 AF017174 CPT1B
2.36 NM_013560 HSPB1
2.26 NM_011658 TWIST1
2.17 BC025600 TMEM119
2.13 BC018375 HES1
1.91 NM_008716 NOTCH3
1.71 NM_008716 NOTCH3
1.71 D45203 D0H4S114
0.46 NM_008625 MRC1
0.38 BC005440 PTGER2
0.35 BI110565 POSTN
Genes confirmed by ChIPseq in italic.
doi:10.1371/journal.pone.0020022.t004
Novel Targets of Notch Signaling in Hematopoiesis
PLoS ONE | www.plosone.org 6 May 2011 | Volume 6 | Issue 5 | e20022Overexpression of Notch 1 alters miRNA expression
during hematopoiesis
Since, the CSL binding sites were mapping to the promoter of
miRNA and close to their genomic loci, we wanted to assess if
overexpression of Notch 1 was influencing miRNA expression.
Comparing the expression profile of miRNA from normal
hematopoietic progenitors (day8-Notch Off) to cells with overex-
pression of activated Notch 1 (day8-Notch On) microarray analysis
showed that 10 genes were differentially expressed by greater than
1.5 fold (Table 9). Four were down regulates (Figure 5a) and six
miRNAs were up-regulated (Figure 5b) as a result of activated
Notch1 overexpression from day 5 to day 8.
MiRNA expression profile of cells with Notch 1
overexpression mimic miRNA expression of cells in a less
mature state
To further confirm the miRNA differentially regulated during
normal hematopoiesis, we selected seven miRNA and used RT-
PCR Taqman assays, to assess their expression on day 5, 6, 7 and
8. These seven miRNA represented four clusters (see figure 4b and
4c). Cluster I are miRNA whose expression is upregulated during
normal hematopoiesis and further upregulated with overexpres-
sion of Notch 1. Cluster II, are miRNA that are also upregulated
during normal hematopoiesis but their expression is attentuated
with the overexpression of Notch 1. Cluster III and IV represent
miRNA whose expression are down regulated during normal
hematopoiesis but the overexpression of Notch 1 either further
upregulates their expression (Cluster III) or attenuates their
expression (cluster IV). Of the seven, microarray analysis showed
that four were down-regulated and three were upregulated (see
figure 5a and 5b). The expression of all seven miRNA as assessed
by the Taqman assays corroborated the microarray assay (see
Table 10 and 11) in their expression patterns. Furthermore,
analysis of miRNA expression during day 6 and 7 in addition to
day 5 and day 8 revealed the kinetics of their expression. For the
down-regulated miRNAs, miR-143 and miR-126b were down
regulated by at least ten fold by day 6. MiR 143 was
downregulated from 10 fold on day 6 to 33 fold by day 7 and
then 35 fold by day 8. Mir-125b was downregulated from 20 fold
on day 6 to 38 fold on day and 33 fold on day 8. Both miR-210
and miR-126 were downregulated less dramatically from day 5 to
day 8 with miR-210 levels experiencing its most dramatic change
Table 5. Differentially regulated genes shown by Chip-ChIP
to be bound by activated Notch responsive CSL.
Affy P-value Foldchange Common Genbank
1418403_at 0.0368 3.665 Adam19 NM_009616
1425405_a_at 0.0415 0.471 Adar AF291876
1421480_a_at 0.0448 1.981 Adarb1 NM_130895
1422514_at 0.0368 2.356 Aebp1 NM_009636
1418204_s_at 0.0495 5.204 Aif1 NM_019467
1449027_at 0.0319 2.351 Arhu NM_133955
1416239_at 0.0277 1.828 Ass1 NM_007494
1419406_a_at 0.012 1.751 Bcl11a NM_016707
1417381_at 0.0484 3.723 C1qa NM_007572
1450355_a_at 0.046 0.556 Capg NM_007599
1448261_at 0.03 3.603 Cdh1 NM_009864
1424051_at 0.0229 3.327 Col4a2 BC013560
1417014_at 0.0435 2.993 Cryac AF250139
1418365_at 0.0011 3.047 Ctsh NM_007801
1448591_at 0.0191 2.227 Ctss NM_021281
1450839_at 0.0177 1.71 D0H4S114 D45203
1434348_at 0.0114 0.553 D17Ertd315e BM206792
1434442_at 0.0025 2.021 D5Ertd593e BB667844
1449222_at 0.0236 0.475 Ebi3 NM_015766
1416552_at 0.0142 4.126 Esg1 NM_025274
1418572_x_at 0.0401 4.021 Fn14-pending NM_013749
1416855_at 0.0283 3.085 Gas1 NM_008086
1418949_at 0.0491 2.314 Gdf15 NM_011819
1421040_a_at 0.0187 47.23 Gsta2 NM_008182
1418102_at 0.0413 2.126 Hes1 BC018375
1415999_at 0.0014 22.973 Hey1 NM_010423
1422943_a_at 0.0289 2.364 Hsp25 NM_013560
1416630_at 0.0102 2.621 Idb3 NM_008321
1426858_at 0.0201 3.048 Inhbb BB353211
1450029_s_at 0.0263 2.314 Itga9 BG067332
1416401_at 0.0033 2.509 Kai1 NM_007656
1448169_at 0.0476 4.659 Krt1-18 NM_010664
1448237_x_at 0.0024 1.711 Ldh2 NM_008492
1451344_at 0.0449 2.172 MGC38046 BC025600
1419402_at 0.0228 1.696 Mns1 NM_008613
1450430_at 0.023 0.456 Mrc1 NM_008625
1448990_a_at 0.0487 1.599 Myo1b AI255256
1454903_at 0.0067 27.008 Ngfr BB151515
1418633_at 0.0058 3.842 Notch1 NM_008714
1421965_s_at 0.009 1.906 Notch3 NM_008716
1449146_at 0.0162 4.568 Notch4 NM_010929
1417986_at 0.0025 5.89 Nrarp BI696369
1423606_at 0.0111 0.35 Osf2-pending BI110565
1436970_a_at 0.0077 2.979 Pdgfrb AA499047
1416321_s_at 0.0439 2.689 Prelp BC019775
1420664_s_at 0.0127 2.544 Procr NM_011171
1424704_at 0.0386 3.184 Runx2 D14636
1419480_at 0.0167 0.389 Sell NM_011346
1423129_at 0.0158 0.486 Shoc2 BQ032685
Affy P-value Foldchange Common Genbank
1460292_a_at 0.0018 6.996 Smarca1 NM_053123
1455900_x_at 0.011 2.803 Tgm2 BB041811
1418726_a_at 0.0225 4.032 Tnnt2 NM_011619
1450782_at 0.0088 5.045 Wnt4 NM_009523
1436791_at 0.0062 5.878 Wnt5a BB067079
1421498_a_at 0.0258 4.111 0610010M13Rik NM_023450
1452747_at 0.0338 0.58 1110012E06Rik BM944122
1438511_a_at 0.0348 3.541 1190002H23Rik BB408123
1420336_at 0.0262 2.093 2010109H09Rik NM_025629
1424770_at 0.0021 1.798 4833423D12Rik BI248947
1418776_at 0.0248 4.486 5830443L24Rik NM_029509
doi:10.1371/journal.pone.0020022.t005
Table 5. Cont.
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difference in the downregulation between day 6 (21.65), day 7
(21.780) and day 8 (21.785). Among the three up-regulated
miRNA, miR-223 progressively increased from day 5 to day 8
whereas miR-144 and miR-451 peaked at day 7.
We have shown that Notch 1 overexpression is associated with
keeping cells in a less differentiated state and the miRNA profiles
corroborate this claim. Notch 1 overexpression is effecting the
timing of miRNA expression during hematopoiesis. When ligand
independent Notch 1 is introduced at day 5, the miRNA
expression is delayed. miR-223 and miR-144 day 8 Notch ON
fold change levels (172 and 193 respectively) mimic day 7 levels
(197 and 180 respectively). For the down-regulated miRNA,
their down regulation was attenuated with overexpression of
Notch 1.
Discussion
The identification of multiple sites with P-values less than 10
212
and the fact that reads were preferentially mapped close to the
TSS indicated that we were likely sequencing true binding sites in
the Chip-Seq experiments. Nonetheless the number of genes that
were shown to be bound by CSL (10,327) seems to be higher than
expected. However, the Gene Ontology analysis indicated that
CSL binding sites are preferentially concentrated in important
signaling pathways which have previously been shown to interact
with the Notch pathway (see Table S1). Therefore, it is our
hypothesis that these large numbers of genes bound by Notch are
in fact likely true targets. In previous studies that used ChIPseq to
identify transcription factor binding sites genome wide, the
number of binding sites identified ranged from 1858 to over
60,000 [101]. For STAT1 there were over 40,000 sites identified
in stimulated Hela S3 cells while there were over 11,000 sites in
unstimulated cells [102]. There were over 11,000 Fox 2a binding
sites identified in adult liver [68]. The number of genes associated
with transcription factor ranged from 1513 to 8411 in a
comprehensive ChIPseq study that mapped 13 transcription
factors in mouse ES cells [101].
The presence of CSL upstream of many genes involved in
signaling pathways indicates that crosstalk between Notch
signaling and other pathways may be at the level of transcription.
It is unlikely that genes of important signaling pathways are
controlled by a single transcription factor. Highly regulated genes
are more likely to be controlled combinatorially by many
transcription factors. This could explain the seemingly contradic-
tory roles that Notch plays in cancer. In some cells, Notch
functions as an oncogene [9] when aberrantly expressed. In other
cell contexts it can function as a tumor suppressor [5]. It is not the
presence of the CSL that solely determines the transcriptional state
of its target genes, but combinations of transcription factors that
converge on a regulatory region collectively that control the
transcription of the gene and hence the transcriptome of a cell.
There were 540 genes that had CSL bound in normal cells but
not in cells with constitutively active Notch. There are two
explanations for this observation. First, CSL dependent Notch
signaling maybe involved in the repression of genes. This
observation would explain a novel mechanism for CSL dependent
Notch signaling. Second, it is possible that the effects of NICD
overexpression could be merely a result of NICD titrating CSL
away from other binding partners [103]. Since constitutively active
Notch is associated with oncogenesis and CSL binding is so
prevalent through out the genome, a possible mechanism of
oncogenesis would be disrupting the homeostasis of CSL binding.
Although the identification of differentially regulated genes by
microarray analysis is important to understand transcriptional
networks, it provides only limited information on the regulation of
Figure 1. Most unique reads map within 1.5 kb of the transcriptional start site. Uniquely-aligned sequences (reads) were counted within a
given 1000 base window relative to genomic positions. A step size of 50 bases was used for window overlap. Poisson distribution [116] was then used
to generate P-values for each 1000 base window and windows were filtered by these values to generate a list of peaks. Significant peaks were
windows with P-value less than 10
212.
doi:10.1371/journal.pone.0020022.g001
Novel Targets of Notch Signaling in Hematopoiesis
PLoS ONE | www.plosone.org 8 May 2011 | Volume 6 | Issue 5 | e20022genes. First, microarray analysis cannot distinguish between direct
and indirect targets. The presence of a CSL binding site in the
promoter of a gene can be indicative of direct regulation by Notch
signaling. CSL binding sites were observed within a region 1.5 kb
of the TSS of several pathways known to crosstalk with Notch such
as Wnt signaling [104] (during hematopoiesis), integrins [105] and
the cadherins [95], and our ChIP-seq study provides the first
evidence that Notch regulates these pathways directly.
Second, microarray analysis can not identify genes that are
essential mediators of transcriptional regulation unless they are
differentially regulated. The CSL transcription factor is a prime
example. It was not among the 158 differentially regulated genes
because Notch does not affect its transcription. However, it is the
main transcription factor mediating Notch regulation. The
potential utility of motif profiling can be highlighted by the fact
that 12 out of 13 transcription factors, including CSL, that were
identified by motif profiling and may be important in mediating
Notch regulation were not seen by microarray analysis because
their expression levels do not change.
Although we cannot conclude from an in silico method such as
CLOVER that the CSL binding sites are actually bound in vivo,w e
can say they represent putative sites that can be bound by CSL.
The success rate of picking bona fide binding sites using in silico
Figure 3. Number of genes with at least one significant peak
within 10 kb of the TSS. Venn diagram shows the overlap between
the three types of significant peaks detected within 10 kb of the TSS of
annotated genes. The overlap regions represent genes with more than
one type of peak within 10 kb of their TSS. 1) On only peak is when
there is a significant peak in the Notch On sample but not in the Notch
Off sample 2) Off only peak is when there is a peak in the Notch Off
sample but not in the Notch On sample 3) Both peak is when there is a
peak in both the Notch On and Notch Off Sample. Red is ‘‘on’’ and
green is control. CBS is defined as CSL Binding Site.
doi:10.1371/journal.pone.0020022.g003
Figure 2. ChIP-seq reads mapping near the TSS. The Integrated Genome Browser was used to visualize the ChIPseq peaks from both the Notch
On and Notch Off sample. (a) TSS of the Myc gene. (b) TSS of the Hey1 gene (c) Hes1 gene and (d) Mns1 gene.
doi:10.1371/journal.pone.0020022.g002
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factor. Some of the latest ChIP-chip findings indicate that these in
vitro derived DNA binding sites may not necessarily represent all
the binding sites of the proteins in vivo. For example, two
independent androgen receptor (AR) ChIP-chip studies showed
that 90% of AR-binding sites did not contain the consensus ARE
motif [106]. Similarly, 90–96% of ChIP-chip identified binding
sites did not contain the in vitro derived E2F consensus [107].
However, other transcription factors show a converse correlation.
Only 20% of the hepatocyte nuclear factor 4a (HNF4a) binding
sites, 10% of the repressor element 1 (REST) binding sites lacked
sequences resembling their respective in vitro derived consensus
sequences [67]. Only 10 out of the 28 genes shown by CLOVER
to have a putative CSL binding site were shown to be bound in
vivo using ChIPseq analysis. Although motif finding algorithms
can be used to assess binding site in silico, they may be limited to a
particular type of binding sites and not the total breadth of binding
sites.
To assess whether the putative CSL binding sites were actually
bound in vivo, we devised a custom ChIP-seq approach which
included a two step IP (Re-ChIP) to capture activated Notch
responsive CSL binding site.
A single IP against CSL will not detect activated Notch-
responsive CSL bound genes because the occupancy of the CSL
binding site does not change in responsive to Notch activation [1].
Therefore, there will be little or no difference comparing CSL
ChIP purified DNA from normal cells to cells with constitutively
active Notch. There are several technical reasons why the two step
IP approach is more likely to capture activated Notch responsive
CSL binding sites. First CSL is a small protein (60 Kd) which is
bound to DNA and is associated with very large repressor
complexes. The crosslinking by formaldehyde makes the CSL
epitope inaccessible by the CSL antibody and therefore the IP
with antibody against CSL is weak (personal communication from
J. Aster AACR 2008). Furthermore, CSL has been detected in the
cytoplasm and it has been proposed by Krejci et al [63] that the
interaction of the CSL activator complex with the binding site
might be dynamic, meaning there is unbound CSL in the nucleus
as well. Both these considerations imply that, in addition to the
epitope being inaccessible, the antibody is being titrated by
unbound CSL. By incorporating an IP step against acetylated
histone H4 (or H3), we created a lysate that will maximize the
likelihood that the CSL antibody will recognize the DNA bound
CSL. The unbound CSL is washed away in the first IP and the
chromatin complexity is reduced to sites that have acetylation at
H4. Thus, we are using biological insight to improve sensitivity.
Coupling our Re-ChIP approach with next-generation sequenc-
ing technologies allowed us to assess genome-wide Notch
responsive CSL binding sites genome-wide. We observed that
the CSL binding sites were preferentially mapping within regions
Table 6. Gene Ontology analysis of genes with at least one On only peak sorted by P-value.
Pathways # P value Enrichment
Cell cycle 23 0.00132 2.9 Regulates Cyclin D3 [69]
p53 pathway by glucose deprivation 22 0.00662 2.7
p53 pathway feedback loops 2 39 0.00084 2.3
Interferon-gamma signaling pathway 21 0.0983 2.3 regulates proliferation and IFN-gamma production [70]
Ubiquitin proteasome pathway 61 9.5E-06 2.2 Induces transcription of SKP2 [71]
Transcription regulation by bZIP TFs 40 0.00289 2.1 N/A
General transcription regulation 29 0.0344 2.1
p53 pathway 74 1.8E-05 2.0 Suppresses p53 in Cancer [72,73]
Ras Pathway 54 0.00031 2.0 Notch/Kras coactivation promotes reprogramming [74,75,76,77]
Hedgehog signaling pathway 24 0.247 2.0 Cross talk in medulloblastoma [5,78,79]
Hypoxia response via HIF activation 20 0.609 2.0 HIF-1alpha interacts and acts in synergy with NICD at Notch targets
[80,81,82]
VEGF signaling pathway 41 0.0326 1.9 Directly regulates of VEGFR-3 [83]
p38 MAPK pathway 33 0.0642 1.9 Suppresses the activity of p38 MAPK [84]
PDGF signaling pathway 96 4.4E-06 1.8 Regulates PDGFb in muscles [85,86]
B cell activation 49 0.0125 1.8 B cell terminal differentiation and Marginal Zone B cells
[87,88,89,90]
FGF signaling pathway 66 0.0159 1.7 Suppresses FGF transformation [91]
Parkinson disease 59 0.025 1.7
Toll receptor signaling pathway 35 0.335 1.7 Regulates Toll receptors and IL-6 [92,93]
Oxidative stress response 36 0.535 1.7
Alzheimer disease-amyloid secretase pathway 34 0.595 1.7
FAS signaling pathway 22 1 1.7
EGF receptor signaling pathway 70 0.013 1.6 Components are direct targets [16]
PI3 kinase pathway 54 0.135 1.6 Activates PI3 Kinase Pathway [94,95]
Dopamine receptor mediated signaling pathway 38 0.48 1.6 Reduces dopaminergic spinal cord neurons [96]
Interleukin signaling pathway 70 0.185 1.5 Binds IL7R gene promoter [97]
doi:10.1371/journal.pone.0020022.t006
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genes.
On Only
Pathways # P value Enrichment
Unclassified 7242 2.43E-09 0.97
Inflammation mediated by chemokine and cytokine signaling pathway 111 1 1.18
Wnt signaling pathway 107 1 0.94
Angiogenesis 97 0.477 1.35
PDGF signaling pathway 96 0.00000444 1.85
Integrin signalling pathway 93 1 1.27
Huntington disease 79 1 1.34
Apoptosis signaling pathway 76 0.194 1.45
p53 pathway 74 0.0000179 1.96
Interleukin signaling pathway 70 0.185 1.48
EGF receptor signaling pathway 70 0.013 1.64
FGF signaling pathway 66 0.0159 1.65
T cell activation 63 1 1.34
Ubiquitin proteasome pathway 61 0.0000095 2.16
TGF-beta signaling pathway 61 0.926 1.42
Parkinson disease 59 0.025 1.68
Ras Pathway 54 0.000306 2.03
PI3 kinase pathway 54 0.135 1.60
Heterotrimeric G-protein signaling -Gi alpha and Gs alpha mediated 54 1 1.09
B cell activation 49 0.0125 1.83
Cytoskeletal regulation by Rho GTPase 43 1 1.14
Heterotrimeric G-protein signaling -Gq alpha and Go alpha mediated 42 1 0.93
VEGF signaling pathway 41 0.0326 1.86
Endothelin signaling pathway 41 1 1.51
Transcription regulation by bZIP transcription factor 40 0.00289 2.11
p53 pathway feedback loops 2 39 0.000841 2.25
Alzheimer disease-presenilin pathway 39 1 0.98
Dopamine receptor mediated signaling pathway 38 0.48 1.64
Oxidative stress response 36 0.535 1.65
Insulin/IGF pathway-protein kinase B signaling cascade 36 1 1.45
Toll receptor signaling pathway 35 0.335 1.72
Alzheimer disease-amyloid secretase pathway 34 0.595 1.67
p38 MAPK pathway 33 0.0642 1.94
General transcription regulation 29 0.0344 2.12
Nicotinic acetylcholine receptor signaling pathway 25 1 0.86
Muscarinic acetylcholine receptor 1 and 3 signaling pathway 25 1 1.36
Metabotropic glutamate receptor group III pathway 25 1 1.08
5HT2 type receptor mediated signaling pathway 24 1 1.18
Hedgehog signaling pathway 24 0.247 2.00
Cadherin signaling pathway 24 0.000102 0.42
Thyrotropin-releasing hormone receptor signaling pathway 23 1 1.21
Insulin/IGF pathway-MAP kinase cascade 23 1 1.07
Cell cycle 23 0.00132 2.94
p53 pathway by glucose deprivation 22 0.00662 2.72
Oxytocin receptor mediated signaling pathway 22 1 1.23
Muscarinic acetylcholine receptor 2 and 4 signaling pathway 22 1 1.25
FAS signaling pathway 22 1 1.75
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binding sites within 300 bp of the TSS. This indicated that the
sequences that were being pulled down with our Re-ChIP
procedure were not mapping randomly throughout the genome.
Furthermore, comparison with the literature showed that CSL
binding relative to the TSS was consistent with the binding site
location of other important developmental transcription factors.
Koudritsky [108] et al. used ChIP-chip data from nine human
transcription factors (OCT4, SOX2, NANOG, HNF1A, HNF4A,
HNF6, FOXA2, USF1 and CREB1) to show that they bind
preferentially to proximal regions to the TSS and with strong
binding within 300 bp of the TSS.
Finally, there seems to be a relation between microRNA and
Notch signaling, although thus far, that relationship has been
studied in regards to how microRNA target Notch1 or its targets.
Here we investigated the alternative by looking which microRNA
may be regulated by Notch1. First, we showed that there were
over 30 microRNA with a CSL binding site within 2 kb of their
transcription start site. That was the impetus for us to profile
microRNA expression in our coculture system. The overexpres-
sion of ligand independent NICD resulted in the differential
expression of 10 microRNAs of which six were upregulated and
four were down regulated. miR-144/miR-451 and miR143 were
most interesting. Both had a CSL binding site within 2 kb of their
transcription start site indicating they maybe direct target and
overexpression of NICD increased both of their expression. Mir-
144 levels were below detection (,100) on the microarray on Day
5 and dramatically increased to 2400 by day 8 during normal
hematopoiesis and its levels reached 4770 with the overexpression
of NICD. Mir-143 levels were highest on day 5 at 2071 and by day
8 its expression levels had decrease to 187 during normal
hematpoiesis and that decrease was attenuated by the overexpres-
sion of NICD. Further studies need to be done if the abberrent
gene regulation caused by overexpression of ligand independent
Notch may be abrogated by controlling the expression of either
miRNA.
Materials and Methods
Motif Analysis
The CLOVER algorithm (Http://zlab.Bu.edu/clover/) was
used to screen a target set of sequences against a motif library to
determine over and under-represented motifs. For the target set,
1.5 kb upstream of transcriptional start site (TSS) sequences of the
Notch regulated genes reported in Ganapati et. [45] were obtained
from the UCSC genome database [109,110] (http://genome.ucsc.
edu/.). Motifs included the JASPAR motif library [111] (n=123)
along with a CSL motif [112]. Number of genes are synomous
with number of Genbank accession number. Therefore, two
Genbank accession number with one common gene name would
be considered two genes.
Background sequences were used for determining statistical
significance. The background included both Mouse Chromosome
19 and 2 kb upstream of all mouse genes. Mouse chromosome 19
is 42.8% C+G from NCBI Build 30, sequences 2000 bp upstream
of mouse genes are 47.8% C+G from UCSC [109,110]. The P
value indicates the probability that the observed over- or under-
representation of a motif is achieved by random selection and was
determined by comparison to mouse chromosome 19 sequence
and 2 kb upstream of all mouse genes.
Cell Culture
ES cell in vitro differentiation and induction of truncated Notch1
expression were as previously described. Briefly, 22.5610
4
undifferentiated ES cells (E14Tg2a ES clone ZEDN1[45])
repressed for ZEDN1 expression were co-cultured on a confluent
layer of OP9 stromal cells in a 225-cm flask in the presence of
100 ng/ml Tet. On day 5 of co-culture, both differentiated ES
cells and the OP9 stromal cells[113] were harvested in fresh
medium. Cells were re-plated in new flask for 20–30 minutes to
separate OP9 cells from ES cells. OP9 cells quickly adhered to the
dish, and ES cells were harvested. Flow cytometry analysis (stained
with anti-Flk-1-PE, CD34-FITC, and CD117-PE (BD Pharmin-
gen, San Diego, http://www.bdbiosciences.com/pharmingen) was
performed on the ES cells harvested from the co-culture on Day 5
to assure that ES cells were differentiating as previously reported.
Then, 8610
6 day 5 ES cells were re-plated on 225-cm flask of
confluent OP9 cells. These day 5 co-cultures were continued in
both Notch-Off (Tet-On) and Notch-On (Tet-Off) conditions until
day 8 when hematopoietic progenitors were harvested for flow
analysis and ChIP assay. Flow analysis [anti-CD117-TC (c-Kit),
anti-CD11b-TC, anti-CD34-PE (Caltag, Burlingame, CA, http://
www.caltag.com), and anti-Ter119-PE (BD Pharmingen)] was
done to ensure that the cells were differentiated as previously
reported. Three separate experiments were performed.
Re-ChIP
ChIP assays were performed as described by using the
chromatin immunoprecipitation assay kit (Upstate Biotechnology,
Waltham, MA) following the protocol supplied by the manufac-
turer with a few modifications including a second IP step. Briefly,
On Only
Pathways # P value Enrichment
Angiotensin II- signaling through G proteins and beta-arrestin 21 1 1.37
Metabotropic glutamate receptor group II pathway 21 1 1.25
Interferon-gamma signaling pathway 21 0.0983 2.28
Axon guidance mediated by semaphorins 21 1 1.50
Beta2 adrenergic receptor signaling pathway 20 1 1.49
Hypoxia response via HIF activation 20 0.609 1.99
5HT1 type receptor mediated signaling pathway 20 1 1.43
Notch signaling pathway 19 1 1.31
doi:10.1371/journal.pone.0020022.t007
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6 day 8 hematopoietic progenitors harvested from the co-
culture were cross-linked in 1% formaldehyde for 10 min at room
temperature, collected, washed and spun down. The pellets were
lysed in SDS lysis buffer at room temperature and sonicated for
four 15 sec pulses (model 300; Fisher Sonic Dismembrator) to
generate DNA with an average length of 0.5–1 kb. The nuclear
lysate was diluted (dilution buffer) and pre-cleared with 100 ul
salmon sperm/ protein A for 2 hrs at 4uC. Supernatants were
incubated with anti-acetyl H4 IgG (Upstate Biotechnology,
Waltham, MA) for 8 hrs at 4uC. Then 80 ul salmon sperm/
protein A were added and incubated for 2 hrs at 4uC. After
extensive washes, and elution (1% SDS, 50 mM NaHCO3), the
eluant was diluted 10X with PBS and incubated with anti-CSL
IgG [114] for 8 hr at 4uC for a second IP. The immunoprecip-
itation step, washes and elution were repeated for the second IP.
The eluants were then incubated at 65uC for 5 hr, followed by
proteinase K treatment for 1 hr at 45uC. DNA fragments were
purified by a chloroform/phenol extraction and an ethanol
precipitation, resuspended in water, and stored at -20uC.
Custom array ChIP-chip
The DNA was then prepared for hybridization according to the
manufacture’s procedure (Combimatrix, Mukilteo, WA). First
DNA from Notch ON and Notch Off cells were amplified using
Ligation Mediated PCR (LMPCR). Then the DNA was labeled
with Cy5 and Cy3 fluorescent dyes respectively. The labeled DNA
Table 8. Differentially regulated genes shown by ChIP-seq to be bound by activated Notch responsive CSL.
Affy ID P-value Foldchange Common Genbank ChiPchip(P)
1438511_a_at 0.034759 3.541205714 1190002H23Rik BB408123 1
1424968_at 0.042857 1.741077596 BC027185 0
1427425_at 0.018985 2.555648905 9130208E07Rik BC026435 na
1420336_at 0.026182 2.092625895 2010109H09Rik NM_025629 1
1425405_a_at 0.04146 0.471274144 Adar AF291876 1
1422631_at 0.01076 4.516146778 Ahr NM_013464 1
1418571_at 0.040063 6.114235523 Fn14-pending NM_013749 1
1418204_s_at 0.049498 5.204132297 Aif1 NM_019467 1
1452747_at 0.033843 0.579953607 1110012E06Rik BM944122 1
1419406_a_at 0.012028 1.750707165 Bcl11a NM_016707 1
1450355_a_at 0.046005 0.555631942 Capg NM_007599 1
1416401_at 0.003304 2.508508142 Kai1 NM_007656 1
1418328_at 0.016035 2.403499989 Cpt1b AF017174 0
1448591_at 0.019113 2.227026837 Ctss NM_021281 1
1438133_a_at 0.048322 2.23959795 Cyr61 BM202770 0
1428306_at 0.007377 2.544732022 5830413E08Rik AK017926 0
1435493_at 0.049644 2.803243131 AA407887 AV297961 0
1435494_s_at 0.136552 2.476938896 AA407887 AV297961 0
1449222_at 0.02364 0.474559067 Ebi3 NM_015766 1
1460356_at 0.013887 2.351055383 Esam-pending AF361882 0
1434348_at 0.011362 0.553337783 D17Ertd315e BM206792 1
1416855_at 0.02831 3.084525151 Gas1 NM_008086 1
1418949_at 0.049119 2.313760679 Gdf15 NM_011819 1
1418350_at 0.035829 2.229833753 Hegfl L07264 0
1418102_at 0.041252 2.126284827 Hes1 BC018375 1
1415999_at 0.001444 22.97309568 Hey1 NM_010423 1
1417014_at 0.043452 2.99304653 Cryac AF250139 1
1417013_at 0.002819 3.18788396 Cryac NM_030704 na
1424112_at 0.00868 1.984754433 Igf2r BG092290 0
1420860_at 0.026274 6.660282574 Itga9 BG067332 1
1450029_s_at 0.113226 2.313648867 Itga9 BG067332 1
1460285_at 0.013047 2.656757581 Itga9 NM_133721 na
1421106_at 0.031982 2.920188923 Jag1 AA880220 0
1417395_at 0.049484 2.221262262 Klf4 BG069413 0
1448169_at 0.047632 4.658619972 Krt1-18 NM_010664 1
1449328_at 0.033057 2.032396003 Ly75 NM_013825 0
1426306_a_at 0.003296 2.440930191 Maged2 AF319976 0
doi:10.1371/journal.pone.0020022.t008
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PLoS ONE | www.plosone.org 13 May 2011 | Volume 6 | Issue 5 | e20022Figure 4. MicroRNA differentially regulated from Day 5 to Day 8. Dendrogram showing a) the 83 differentially regulated microRNAs from day
5 to day 8. b) microRNAs that were differentially regulated comparing Day 8 Notch ON to Notch OFF and c) the microRNAs used for real-time PCR
analysis. Data analyses were performed by using DNA-Chip Analyzer 1.3 [117]. The thresholds for selecting significant genes were set at a relative
difference of .1.5-fold, an absolute difference of .100 signal intensity, and P,0.05.
doi:10.1371/journal.pone.0020022.g004
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PLoS ONE | www.plosone.org 14 May 2011 | Volume 6 | Issue 5 | e20022Figure 5. Seven MicroRNA expression on day 5, 6, 7 and 8. Seven mature microRNAs including a) four downregulated and b) three
upregulated that whose expression was analyzed using Taqman miRNA expression assay on day 5,6,7 and 8. The expression of the miRNA was
normalized against the expression level of the control miRNA snoRNA202 (AF357327) and presented as the mean normalized expression.
doi:10.1371/journal.pone.0020022.g005
Table 9. miRNAs differentially regulated by overexpression of ligand independent Notch1.
probe set Day 8 Notch OFF Day 8 Notch ON Day 8 Notch ON versus Notch OFF P value
mmu-miR-210 132.77 306.83 2.31 0.0083
mmu-miR-451 16123.4 35723.37 2.22 0.0258
mmu-miR-486 69.59 142.45 2.05 0.0365
mmu-miR-125b-5p 187.47 382.53 2.04 0.0506
mmu-miR-2133 785.97 1450.26 1.85 0.0255
mmu-miR-295 91.52 163.06 1.78 0.0163
mmu-miR-126-5p 386.06 255.75 21.51 0.0044
mmu-miR-126-3p 2791.95 1816.94 21.54 0.0063
hsa-miR-629* 151.56 83.97 21.8 0.0048
mmu-miR-223 3566.25 1928.69 21.85 0.0162
doi:10.1371/journal.pone.0020022.t009
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PLoS ONE | www.plosone.org 15 May 2011 | Volume 6 | Issue 5 | e20022fragments were then used to probe custom tiling (tiled every 50 bp)
arrays (Combimatrix, Mukilteo, WA) containing 4880 unique
probes representing 1.5 kb promoter sequences of Notch regulated
genes as well as background regions. The probes on the array are
repeated at least once to cover the 12K probe custom array.
Custom array analysis
For normalization, each probe was divided by the medium Cy5
(or Cy3) signal for the array. Identical probes on an array with a
CV of greater than 0.3 were excluded in the analysis. Since three
independent experiments were performed, the values for each
probe across the three arrays were averaged for a given
experimental condition. For each experiment, there were two
arrays hybridized. One array was hybridized with ChIP purified
DNA from anti-CSL (single IP) and the other array was hybridized
with ChIP purified DNA from 2 cycle IP (anti-acetyl H4 IP
followed by anti-CSL IP). The average values for each probe were
used to determine enrichment. For each probe, values from the
Notch On condition (activated Notch) were divided by values from
the Notch Off condition (control cells) to determine a ratio. The
log 2 ratio of Notch On to Notch Off was used to determine
binding. ChIPOTle analysis [115], which identifies peaks using a
sliding window approach, was performed for each array . The
window was set to the average shear length of the DNA (250 bp)
and the step was set to the probe size (50 bp). We used the
Gaussian distribution to model the background or non-enriched
population because it is the most powerful approach in
ChIPOTLe for estimating the P-value for enrichment. It assumed
the background to a symmetric Gaussian distribution about the
mean of zero. The P-values reported by ChIPOTle are corrected
for multiple comparisons using the conservative Bonferroni
correction. Under the null hypothesis, the distribution of the
average log2 ratio within each window is again Gaussian, with
mean zero and Variance equal to the variance of a single log ratio
divided by the number of elements in the window. Thus the
nominal P-value for a window with average ratio w can be
calculated using the standard error function (ERF) as follows:
Pwindow~1{ERF   w w 
s=
ﬃﬃﬃ
n
p
  
where s is the standard deviation for the background distribution,
and n is the number of microarray elements used in the window.
ChIP-seq
ChIP-seq libraries were made from the purified Re-ChIP DNA
fragments using the Illumina ChIP-seq Sample Prep Kit following
the manufactures procedure. After the Re-ChIP DNA fragments
were end-repaired, Illumina adapters were ligated to amplify the
DNA. The amplified DNA was run on a 2% gel and fragments
150–300 bp in size were purified and sequenced on the Illumina
Genome Analyzer according to the manufacturer’s instruction.
The resulting flow-cell was sequenced for 36 cycles to generate 36-
bp reads. The sequencing was performed using the Jonsson
Cancer Center Gene Expression Shared Resource (http://www.
cancer.ucla.edu/Index.aspx?page=150).
The Eland alignment tool was used to align the first 32 bp of
every read to the mouse reference genome (NCBI build 37, mm9)
allowing for 2 base mismatches per sequence. Only uniquely
mapped reads were considered for further analysis.
Uniquely-aligned sequences (reads) were then subjected to a
peak analysis algorithm which counts all reads within a given 1000
base window relative to genomic positions. A step size of 50 bases
was used for window overlap. The Poisson distribution [116] was
used to generate P-values for each 1000 base window using the
observed and expected counts (the average number of reads in a
1 kb window in the genome) and windows were filtered by these
values to generate a list of peaks.
Peaks were defined by several criteria: (a) a window P-value less
than 10
212, (b) a Notch On/Notch Off difference greater than 2
and (c) a window mapability greater than 25% (i.e. more than 25%
of the 32mers in the window were unique to the genome).
This list of peak positions was then filtered by their genomic
positions relative to +/2 10 kb of all known TSS (Fig. 4.1). The
same process was repeated using an equal number of randomly
sampled 32 base sequences as a control to determine the false
discovery rate of the peak-finding algorithm (data not shown),
which was less than 1%.
Table 10. miRNA differentially regulated during normal hematopoiesis and affected by the overexpression of activated Notch.
probe set Day 5 Day 8 Notch OFF Day 8 Notch ON
Day 8 Notch OFF
versus Day 5 P value
Day 8 Notch ON versus
Notch OFF P value
mmu-miR-451 141.46 16123.4 35723.37 113.98 0.0024 2.22 0.0258
mmu-miR-223 24.31 3566.25 1928.69 146.73 0.0071 21.85 0.0162
mmu-miR-144 36.83 2409.56 4770.81 65.42 0.0489 1.98 0.2094
mmu-miR-126-3p 3155.6 2791.95 1816.94 21.13 0.5520 21.54 0.0063
mmu-miR-210 573.25 132.77 306.83 24.32 0.0099 2.31 0.0083
mmu-miR-143 2071.2 39.64 103.9 252.25 0.0170 2.62 0.0637
mmu-miR-125b-5p 7859.6 187.47 382.53 241.93 0.0483 2.04 0.0506
doi:10.1371/journal.pone.0020022.t010
Table 11. Timecourse of miRNA expression from Day 5 to
Day 8 and the effect of overexpression of activated Notch.
Day 5 Day 6 Day 7
Day 8
Notch OFF
Day 8
Notch ON
mir-223 1.00 70.21 197.62 372.17 172.26
mir-451 1.00 53.59 133.43 101.39 209.60
mir-144 1.01 110.24 180.22 84.87 193.33
mir-126 1.00 21.65 21.78 21.79 22.91
mir-210 1.00 25.47 23.37 24.30 22.22
mir-125b 1.00 220.03 238.33 235.60 226.03
mir-143 1.00 213.63 233.35 236.54 222.13
doi:10.1371/journal.pone.0020022.t011
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Total RNAs were isolated by TRIzol (Invitrogen) from the ES/
OP9 coculture at day 5, dau 8 Notch-On and Day 8 Notch Off.
The labeled miRNAs were hybridized to miRCURY
TM locked-
nucleic acid array version 8.1 (Exiqon) according to the
instructions of the manufacturer. Data analyses were performed
by using DNA-Chip Analyzer 1.3 [117]. The thresholds for
selecting significant genes were set at a relative difference of .1.5-
fold, an absolute difference of .100 signal intensity, and P,0.05.
All data is MIAME compliant and the raw data has been
deposited in Gene Expression Omnibus (GEO) (GEO Accession
# GSE28338), a MIAME compliant database.
TaqmanH miRNA Expression Assays
RNA was reverse-transcribed using specific miRNA stem-loop
primers [118] and the TaqmanH miRNA reverse transcription kit
(Applied Biosystems). Mature miRNA expression was measured
with TaqmanH microRNA assays (Applied Biosystems) according
to the manufacturer’s instructions. The expression of the miRNA
was normalized against the expression level of the control miRNA
snoRNA202 (AF357327) and presented as the mean normalized
expression.
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